Ambrx Biopharma Inc. to Present at Oppenheimer’s 32nd Annual Healthcare Conference
March 08 2022 - 8:00AM
Business Wire
Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage
biopharmaceutical company using an expanded genetic code technology
platform to create Engineered Precision Biologics, today announced
that Feng Tian, Ph.D., Chairman of the Board, President, and CEO of
Ambrx, will present at Oppenheimer’s 32nd Annual Healthcare
Conference taking place March 15-17, 2022.
Dr. Tian is scheduled to present on Thursday, March 17, at 12:40
p.m. Eastern Time.
Interested parties can access the live webcast for this
conference from the Investor Relations section of the company's
website at www.ambrx.com. The webcast replay will be available
after the conclusion of the panel discussion for approximately 90
days.
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical stage biopharmaceutical company using an
expanded genetic code technology platform to discover and develop
Engineered Precision Biologics. These include next generation
antibody drug conjugates (ADCs), bispecifics, targeted
immuno-oncology therapies, novel cytokines to modulate the immune
system, and long-acting therapeutic peptides for metabolic and
cardiovascular disease. Ambrx is advancing a robust portfolio of
clinical and preclinical programs designed to optimize efficacy,
safety and ease of use, in multiple therapeutic areas, including
its lead product candidate ARX788. In addition, Ambrx has clinical
collaborations with multiple partners, for drug candidates
generated using Ambrx technology. For more information, please
visit www.ambrx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220308005346/en/
INVESTORS Laurence Watts Managing Director Gilmartin Group, LLC.
619-916-7620 ir@ambrx.com
MEDIA media@ambrx.com
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
From Sep 2023 to Sep 2024